CVRx (NASDAQ:CVRX) Announces Quarterly Earnings Results

Key Points

• CVRx missed quarterly earnings expectations, reporting an adjusted loss of $0.53 per share versus the $0.52 consensus, while revenue of $15.71 million slightly exceeded estimates.
• The company lowered 2026 revenue guidance to $58 million–$60 million, citing sales-team turnover, slower territory-manager ramp-ups and weaker expected second-half performance.
• Reimbursement remains mixed: a major Medicare Advantage payer’s prior-authorization changes reduced approval rates below 30%, although approval trends with other payers are improving; CVRx also disclosed a Department of Justice inquiry into certain sales and marketing practices.

CVRx (NASDAQ:CVRX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.01), FiscalAI reports. The business had revenue of $15.71 million during the quarter, compared to analyst estimates of $15.55 million. CVRx had a negative net margin of 89.14% and a negative return on equity of 120.76%.

Here are the key takeaways from CVRx's conference call:

• 2026 revenue guidance was lowered to $58 million–$60 million, with third-quarter revenue expected at $13.5 million–$14.5 million, reflecting weaker anticipated second-half performance.
• Sales execution has been hampered by high turnover and slower-than-expected ramping of new territory managers, particularly in several regions with less-tenured leadership; CVRx does not expect to add sales territories for the rest of 2026.
• A major Medicare Advantage payer’s use of new prior-authorization tactics has pushed its 30-day approval rate below 30%, making physicians more hesitant to recommend Barostim for patients covered by that plan.
• Reimbursement trends outside that payer are improving, including a 60% overall Medicare Advantage 30-day approval rate, approval rates above 90% with Humana, approximately 96% payment across traditional Medicare contractors, and higher inpatient payment rates.
• CVRx reported second-quarter revenue of $15.7 million, up 16% year over year, and said the BENEFIT-HF trial is ahead of expectations for site activation and enrollment; however, the company also disclosed a Department of Justice civil investigative demand related to certain sales and marketing practices.

CVRx Stock Performance

NASDAQ CVRX traded up $0.36 during trading on Thursday, reaching $5.94. The company's stock had a trading volume of 452,909 shares, compared to its average volume of 218,213. The firm has a 50 day moving average price of $5.26 and a 200 day moving average price of $6.52. CVRx has a 12 month low of $4.37 and a 12 month high of $11.30. The firm has a market capitalization of $157.65 million, a price-to-earnings ratio of -2.94 and a beta of 0.81. The company has a current ratio of 10.20, a quick ratio of 8.89 and a debt-to-equity ratio of 2.01.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of CVRx in a report on Monday. Wall Street Zen raised shares of CVRx from a "sell" rating to a "hold" rating in a report on Saturday, June 27th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $10.00 price target on shares of CVRx in a research note on Tuesday, April 14th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, CVRx presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.50.

Hedge Funds Weigh In On CVRx

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in shares of CVRx by 6.4% during the 2nd quarter. Geode Capital Management LLC now owns 382,437 shares of the company's stock valued at $2,249,000 after acquiring an additional 23,079 shares during the period. XTX Topco Ltd acquired a new stake in shares of CVRx during the 2nd quarter worth $155,000. Marshall Wace LLP increased its position in shares of CVRx by 238.1% in the second quarter. Marshall Wace LLP now owns 350,080 shares of the company's stock worth $2,058,000 after purchasing an additional 246,548 shares during the period. Cresset Asset Management LLC raised its stake in CVRx by 3.5% in the second quarter. Cresset Asset Management LLC now owns 53,542 shares of the company's stock valued at $315,000 after purchasing an additional 1,823 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in CVRx by 7.6% in the second quarter. Bank of America Corp DE now owns 89,049 shares of the company's stock valued at $524,000 after purchasing an additional 6,312 shares in the last quarter. Institutional investors own 75.27% of the company's stock.

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company's flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body's natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source